Authors’ reply to Braillon and Bewley
BMJ 2016; 353 doi: https://doi.org/10.1136/bmj.i2583 (Published 11 May 2016) Cite this as: BMJ 2016;353:i2583
- Simone N Vigod, assistant professor, psychiatrist, Shirley Brown clinician scientist1,
- Claire A Wilson, academic clinical fellow2,
- Louise M Howard, NIHR research professor, professor in women’s mental health, and consultant perinatal psychiatrist2
- 1Department of Psychiatry, Faculty of Medicine, University of Toronto; Women’s College Hospital and Women’s College Research Institute, ON, Canada M5S 2B1
- 2Section of Women’s Mental Health, King’s College London, London, UK
- simone.vigod{at}wchospital.ca
Firstly, we agree with Braillon and Bewley that more is needed to support education in this area at the point of care,1 2 and our teams have been working on developing an online patient decision aid that aims to help women make decisions about drugs during pregnancy in collaboration with their providers.3 This tool is currently being evaluated, and one main advantage is that its electronic nature will enable timely updating when new evidence emerges and broad access. Because of the rapidly changing literature, with the harms and benefits of antidepressant use in pregnancy being inconsistently reported, we would also argue that printed …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £164 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£30 / $37 / €33 (excludes VAT)
You can download a PDF version for your personal record.